Literature DB >> 33895315

Which factors matter the most? Revisiting and dissecting antibody therapeutic doses.

Yu Tang1, Xiaobing Li2, Yanguang Cao3.   

Abstract

Factors such as antibody clearance and target affinity can influence antibodies' effective doses for specific indications. However, these factors vary considerably across antibody classes, precluding direct and quantitative comparisons. Here, we apply a dimensionless metric, the therapeutic exposure affinity ratio (TEAR), which normalizes the therapeutic doses by antibody bioavailability, systemic clearance and target-binding property to enable direct and quantitative comparisons of therapeutic doses. Using TEAR, we revisited and dissected the doses of up to 60 approved antibodies. We failed to detect a significant influence of target baselines, turnovers or anatomical locations on antibody therapeutic doses, challenging the traditional perceptions. We highlight the importance of antibodies' modes of action for therapeutic doses and dose selections; antibodies that work through neutralizing soluble targets show higher TEARs than those working through other mechanisms. Overall, our analysis provides insights into the factors that influence antibody doses, and the factors that are crucial for antibodies' pharmacological effects.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33895315      PMCID: PMC8410626          DOI: 10.1016/j.drudis.2021.04.022

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   8.369


  66 in total

Review 1.  Drug Development of Therapeutic Monoclonal Antibodies.

Authors:  Diane R Mould; Bernd Meibohm
Journal:  BioDrugs       Date:  2016-08       Impact factor: 5.807

Review 2.  Next generation antibody drugs: pursuit of the 'high-hanging fruit'.

Authors:  Paul J Carter; Greg A Lazar
Journal:  Nat Rev Drug Discov       Date:  2017-12-01       Impact factor: 84.694

Review 3.  Clinical Development Strategies and Outcomes in First-in-Human Trials of Monoclonal Antibodies.

Authors:  Diego Tosi; Yassine Laghzali; Marie Vinches; Marie Alexandre; Krisztian Homicsko; Angelica Fasolo; Gianluca Del Conte; Anna Durigova; Nadia Hayaoui; Sophie Gourgou; Luca Gianni; Caroline Mollevi
Journal:  J Clin Oncol       Date:  2015-05-26       Impact factor: 44.544

Review 4.  Optimal Dosing for Targeted Therapies in Oncology: Drug Development Cases Leading by Example.

Authors:  Jeffrey R Sachs; Kapil Mayawala; Satvik Gadamsetty; Soonmo Peter Kang; Dinesh P de Alwis
Journal:  Clin Cancer Res       Date:  2015-11-23       Impact factor: 12.531

5.  Impact of intrinsic affinity on functional binding and biological activity of EGFR antibodies.

Authors:  Yu Zhou; Anne-Laure Goenaga; Brian D Harms; Hao Zou; Jianlong Lou; Fraser Conrad; Gregory P Adams; Birgit Schoeberl; Ulrik B Nielsen; James D Marks
Journal:  Mol Cancer Ther       Date:  2012-05-07       Impact factor: 6.261

6.  89Zr-Lumretuzumab PET Imaging before and during HER3 Antibody Lumretuzumab Treatment in Patients with Solid Tumors.

Authors:  Frederike Bensch; Laetitia E Lamberts; Michaël M Smeenk; Annelies Jorritsma-Smit; Marjolijn N Lub-de Hooge; Anton G T Terwisscha van Scheltinga; Johan R de Jong; Jourik A Gietema; Carolien P Schröder; Marlene Thomas; Wolfgang Jacob; Keelara Abiraj; Celine Adessi; Georgina Meneses-Lorente; Ian James; Martin Weisser; Adrienne H Brouwers; Elisabeth G E de Vries
Journal:  Clin Cancer Res       Date:  2017-07-21       Impact factor: 12.531

7.  Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy.

Authors:  Shruti Agrawal; Yan Feng; Amit Roy; Georgia Kollia; Brian Lestini
Journal:  J Immunother Cancer       Date:  2016-11-15       Impact factor: 13.751

Review 8.  Receptor occupancy assessment by flow cytometry as a pharmacodynamic biomarker in biopharmaceutical development.

Authors:  Meina Liang; Martin Schwickart; Amy K Schneider; Inna Vainshtein; Christopher Del Nagro; Nathan Standifer; Lorin K Roskos
Journal:  Cytometry B Clin Cytom       Date:  2015-07-31       Impact factor: 3.058

9.  Clonal replacement of tumor-specific T cells following PD-1 blockade.

Authors:  Kathryn E Yost; Ansuman T Satpathy; Daniel K Wells; Yanyan Qi; Chunlin Wang; Robin Kageyama; Katherine L McNamara; Jeffrey M Granja; Kavita Y Sarin; Ryanne A Brown; Rohit K Gupta; Christina Curtis; Samantha L Bucktrout; Mark M Davis; Anne Lynn S Chang; Howard Y Chang
Journal:  Nat Med       Date:  2019-07-29       Impact factor: 53.440

10.  Tumor penetration and epidermal growth factor receptor saturation by panitumumab correlate with antitumor activity in a preclinical model of human cancer.

Authors:  Daniel J Freeman; Kevin McDorman; Selam Ogbagabriel; Carl Kozlosky; Bing-Bing Yang; Sameer Doshi; Juan Jose Perez-Ruxio; William Fanslow; Charlie Starnes; Robert Radinsky
Journal:  Mol Cancer       Date:  2012-07-25       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.